KIDWAI MEMORIAL INSTITUTE OF ONCOLOGY

DR.M.H.MARI GOWDA ROAD, BANGALORE-560029.

BIDDING DOCUMENT

ENQUIRY **No. KMIO/SME(1)/Tender/Anti Cancer Drugs/14/2013-2014**

FOR PROCUREMENT OF ANTI CANCER DRUGS & REAGENTS TO BLOOD BANK

DIRECTOR
KIDWAI MEMORIAL INSTITUTE OF ONCOLOGY,
BANGALORE-29.

Cost of Bid Document Rs. 3,000-00

KIDWAI MEMORIAL INSTITUTE OF ONCOLOGY

DR. M.H. MARIGOWDA ROAD, BANGALORE – 560 029

Phone: 26560733

No. KMIO/SME(1)/Tender/Anti Cancer Drugs/14/2013-14 Dated: 16.01.2014

e-PROCUREMENT TENDER NOTIFICATION

Online Tenders are invited in **TWO Bid System** for the supply of following through GOK e-Procurement.

Sl. No.	Name of the Item	
01	Anti Cancer Drugs - Package – I	
02	Reagents to Blood Bank - Package - II	

The Bid Document will be available in online from 27.01.2014 to 28.03.2014 till 11-30 A.M. Bidders can view and download the Bid Document from the Website https://eproc.karnataka.gov.in Bids have to be submitted through e-Procurment Portal and the bidders should pay tender document fee of Rs. 3,000/- by cash at Anikethana Cash Counter, KMIO., Bangalore or D.D. in favour of the Director, KMIO., Bangalore. The last date and time of Receipt of Bid through e-Procurerment Portal is 28.03.2014 at 11-30 A..M. Tender accepting Authority reserves the right to accept/reject/cancel the tender without assigning any reason thereof.

DIRECTOR.

TENDER FORM

KIDWAI MEMORIAL INSTITUTE OF ONCOLOGY,

DR.M.H.MARIGOWDA ROAD, BANGALORE-560029.

(Registered under Karnataka Societies Registration Act 1960, Reg.No.S475/79-80)

PHONE: 26560722(Director) EXCHANGE : 26094000

FAX : 91-80-26560723 Email : root@kidwai.kar.nic.in

Notification : FOR SUPPLY OF ANTI CANCER DRUGS / REAGENTS TO BLOOD BANK

KIDWAI MEMORIAL INSTITUTE OF ONCOLOGY

DR. M.H. MARIGOWDA ROAD, BANGALORE – 560 029

FOR THE SUPPLY OF ANTI CANCER DRUGS / REAGENTS TO BLOOD BANK

SCHEDULE OF EVENTS

Sl. No.	Events	Date & Timings	Venue
01	Date of down loading of Tender Document	27.01.2014 from 11-00 A.M.	
02	The Last Date for uploading the Tender Document	28.03.2014 till 11-30 A.M.	
03	Pre-Bid Meeting	19.03.2014 at 11:30 A.M.	Seminar Hall KMIO.,
04	Time & Date of Opening of the Tender (Technical Bid)	31.03.2014 at 11-30 A.M.	Computer Room Room No.; 59
05	Time & Date of Opening of Tender (Financial Bid)	16.04.2014 at 11-30 A.M.	Computer Room Room No. 59

Address for Communication:

DIRECTOR
KIDWAI MEMORIAL INSTITUTE OF ONCOLOGY,
DR. M.H. MARIGOWDA ROAD,
BANGALORE – 560 029.
Phone: Director : 080-26560722
Financial Adviser : 080-26560733

CHECKLIST

DOCUMENTS TO BE UPLOADED ALONG WITH "TECHNICAL BID" (FIRST COVER) AND " PRICE BID" (SECOND COVER)

(Enclose the papers in following Order

1.TECHNICAL BID (FIRST COVER) ….

Sl. No.	Name of the Drugs quoted	
1	a) EMD online Payment Details b) Name of the Bank & Branch	
2.	Latest Sales Tax Clearance certificate Annual/Quarterly	
3.	Attested copy of Manufacturer license if it is manufacturing unit	
4.	Authorized Agency certificate from Principal Manufacturer in original in format – X	
5.	ISI/ISO/CE/FDA Drugs Licence GMP certificates if any	
6	Specification / Prerequisites & - Technical Specification for procurement of Drugs.	
7.	Quality Analysis by Accredited Labs.	

II. PRICE BID (SECOND COVER)

1	Price of Anti Cancer Drugs / Blood Bank Reagents including all charges	

Signature of the Tenderer

SECTION-I

INVITATION TO TENDERERS

1. The Tender inviting Authority of Kidwai Memorial Institute of Oncology, Dr. M.H. Marigowda Road, Bangalore-560 029, hereby invites sealed Tenders from the Manufacturers and /or IMPORT LICENCE HOLDERS IN THE CASES OF IMPORTED FORMULATIONS and or their local authorized agents for the supply of Anti Cancer Drugs / Reagents to Blood Bank.
2. Tenderers are free to quote for any or all of the items listed in Section-V & VI & the evaluation of Tender will be conducted as per item basis
3. Tenders of only those tenderers who fulfils the Terms and conditions will be considered for evaluation.
4. Eligible tenderers interested may obtain further information from the Office of the Director, Kidwai Memorial Institute of Oncology, Dr. M.H. Marigowda Road, Bangalore-560 029.
5. A complete set of Tender documents may be down loaded from the Website https://eproc.karnataka.gov.in schedule of events **from 27.01.2014 to 28.03.2014 till 11-30 A.M. and date of opening of Tender (Technical Bid) on 29.03.2014 at 11-30 A.M. and bidder should pay Tender Document Fee of Rs .3,000=00 (**Rupees Three Thousand Only) by cash at Anikethana Cash Counter KMIO., Bangalore or DD Drawn on any Nationalized Bank in favour of **"Director, Kidwai Memorial Institute of Oncology, Bangalore"** payable at Bangalore.
6. Last date and time for submission of tender is **28.03.2014 till 11:30 A.M.**
7. Technical Bid will be Opened on **31.03.2014 at 11-30 A.M.**

SECTION-II

TERMS AND CONDITIONS

1**. TENDER TO FULFILL ALL CONDITIONS** :

The tender shall be submitted only if the Tenderer is agreeable to all the Terms and Conditions of this Tender, which included the description of the items mentioned therein. The Tenderer shall fulfils all the terms and conditions prescribed in Section - I & Section - II.

Tenderers shall sign all the pages of Tender Document including prerequisites' and Technical Specification for procurement of Drugs

2. **DOCUMENTS TO ACCOMPANY TENDER:**

The Tenderer shall submit the following documents in the manner described in Section -III

3. LANGUAGE :

The language of the Tender shall be in English.

4. EXTENSION OF DEADLINE :

The Director, Kidwai Memorial Institute of Oncology, tender inviting authority may, at his discretion, extend the deadline for submission of tenders in which case, all rights and obligations of the Director, Kidwai Memorial Institute of Oncology, tender inviting authority and tenderers previously subject to the deadline, will thereafter be subject to the such extended deadline.

5. LATE TENDERS :

Any tender received by the Authority after the deadline will be rejected or returned.

6. **TENDERS MAY BE REJECTED AT DISCRETION :**

The Director, Kidwai Memorial Institute of Oncology, Tender inviting authority reserves the right to reject the tenders or to accept the tenders for the supply of all goods or any one or more of the goods tendered for in a tender without assigning any reason.

7. **IF HOLIDAY IS DECLARED** :

In the event of the Date of submission or opening of the tender, being declared as a Holiday for the office of the Director, Kidwai Memorial Institute of Oncology, tender inviting authority, the due date for submission of tender and opening of tender will be the following working day at the appointed time.

8. .**COST OF TENDER** :

The Tenderer shall bear all costs associated with the preparation and submission of his tender and the Director, Kidwai Memorial Institute of Oncology will in no case, be responsible or liable for these costs, regardless of the conduct or out come of the Tendering process.

09. **SUBMISSION OF SAMPLE ALONGWITH TENDER OFFER**:

The Tenderer shall submit sample where ever necessary at the time of evaluation at their cost.

10. **INELIGIBILITY OF THE BLACK LISTED:**

(a) The Firms/Manufacturers who have been notified as BLACK-LISTED are not eligible for participation in this tender.
(b) Tender to be quoted in the Generic names of Drugs & Reagents. The Tenderer should quote the rates for the same.

Note:

1. The rates quoted shall be inclusive of Excise Duty & Sales Tax payable if any
2. The quotations shall be in words as well as in figures in a legible manner in English language.
3. All corrections shall be duly attested with full signature

4. No column shall be left blank
5. The rates quoted should not be linked to the quantum of the order or destination
6. The rates quoted shall be F.O.R. destination of the purchaser (i.e., where the sub stores are situation at district level)
7. The rates quoted should include all charges such as packing, freight, cooly, hire etc., and for free delivery at this Institute.

11. **EARNEST MONEY DEPOSIT through e-Portal :**

Sl. No.	**Name of the Item**	EMD Amount
01	Anti Cancer Drugs	Rs. 2,00,000-00
02	Reagents to Blood Bank	Rs. 25,000-00

12. **FALL CLAUSES :**

1. The price quoted shall not in any case exceed the maximum wholesale ceiling price (bulk), if any, fixed by the Government of India, or the State Government or the whole sale price fixed by the Tenderer for General Market.

a) The rate quoted for the product in no event shall exceed the lowest price at which the Tenderer sells his products of identical description to any other person, state, union territory, corporation, board, university, trust, local authority, company or any other including his own dealer, distributor, stockists or agent.
b) If at any time, the tenderer reduces the sale price of such products to any other persons, state, union territory, corporation, board, university, trust, local authority, company, and any other including his own dealer, distributor, stockists, agent at price lower than the price quoted then the price should be automatically reduced to that of sale price of such product to any such other persons mentioned.

2. Request for price revision due to increase in Excise Duty will be considered only for such batch or batches of products, which have incurred such increased Excise Duty. It shall be subject to production of relevant orders of authority concerned.

3. The Tenderer pleading for such price revision shall produce all the necessary comparative documents issued by the competent Authority and shall also provide such additional information/documents which the Director, Kidwai Memorial Institute of Oncology Tender Inviting

Authority may desire for taking decisions.

13. **GOODS TO BE PACKED:**

1. Anti Cancer Drugs & Reagents requiring refrigeration or freezing for stability should specifically indicate storage requirements on labels and containers to ensure stability in transit for the point of shipment to the destination.

2. In the case of Anti Cancer Drugs & Reagents, the packing components which come in direct contact with the Drug (containers and closures)shall confirm to specifications stated in Section V of this Tender. All packing must be tamper-proof.

3. The Tenderer shall provide such packing for the goods including the outer bulk packs, as it required to prevent their damage or deterioration during transit to their final destination as indicated in the orders.

4. The packing shall be sufficient to withstand, without limitation, rough handling during transit and exposure to weather conditions, prevailing in the Karnataka state during transit and storage.

5. The goods shall be packed at his own cost in such a manner as to ensure delivery in good condition.

6. The packing shall be in accordance with the General specifications and individual specifications shown against each item in Section V to VII.

14. **EXPIRY DATE :**

1. All products must indicate the Dates of Manufacture and Expiry. All products must arrive at the purchasers point with a remaining shelf life of at least 80% (eighty percent) of the total stipulated shelf life.

2. The Anti Cancer Drugs & Reagents having date of expiry should be replaced with fresh stocks from the latest batch if returned 3 months before the date of expiry.

15. **QUALITY, TESTING & INSPECTION** :

a) The Director reserve the right to test each or batches selected at random of the consignment received either at the time of receiving the goods or at any time during shelf life of the product for test and analysis at any laboratory approved under the Drugs and Cosmetic act and Rules.
b) If the sample or samples is/are declared to be "NOT OF STANDARD QUALITY" or spurious or adulterated or misbranded, such batch/batches will be deemed to be rejected goods.
c) During the validity period of the tender, the decision of the Director will be final with reference to the quality of the goods supplied.

16. VALIDITY OF QUOTATION :

The initial period of validity of quotation shall not be less than 24 Months it may be extended for a maximum period 3 months.

17. EVALUATION :

Cover-I will be opened first by the tender inviting authority and evaluated technically and the cover-II will be opened only of those who qualify technically and commercially as per terms as specified in the tender document.

18. INTIMATION TO SUCCESSFUL TENDERER :

The acceptance, if any of the tender will be informed by the Director, Kidwai Memorial Institute of Oncology, tender accepting authority, by writing to the successful tenderers.

19. ORDERS DELIVERY SCHEDULES AND PENALTY :

1. The Director, Kidwai Memorial Institute of Oncology & tender inviting authority reserves the right to order for only such quantity as may be necessary and tenderer is bound to supply the ordered quantity only. Quantities supplied in excess will not be paid for.

2. The supply should be completed within 30 days from the date of intimation of the order to the tenderer.

20. PAYMENT :

Payment will be made only after receipt of the goods in good condition. The decision of the Director, Kidwai Memorial Institute of Oncology on the

question of the good condition of the goods shall be final and binding on the tenderer.

21. DEFAULT AND PENALTIES :

If any goods supplied by the tenderer is partially or wholly used after supply and is subsequently found to be NOT AS PER DESCRIPTIONS, unsound, inferior in quality or description or otherwise faulty or unsafe or unfit for use, then, an amount equal to the cost of similar articles in good condition along with penalty of ten percent (10%) will be levied to the tenderer, if the payment has already been made.

The Director, Kidwai Memorial Institute of Oncology reserves the right to cancel the supply orders, or terminate the orders, if the tenderer is found guilty of the violation of the tender conditions agreed to and the undertakings furnished.

Any financial loss incurred by the Institute consequent to the above action shall be recoverable from such defaulting tenderer out of the deposits furnished under this tender or any other tender or the payments pending with the Director.

22. BLACK LISTING :

The Director, Kidwai Memorial Institute of Oncology & Tender inviting authority reserves the right to blacklist any tenderer either in whole or in part limiting to specified product/products for breach of any of the terms and conditions of the tender.

Such blacklisted firms/person/companies are not eligible to participate, tenders for subsequent 5 years.

23. DISPUTES AND JURISDICTION :

In the event of any dispute arising out of the terms and conditions of the tender, such dispute shall be subject only to the jurisdiction of courts in Bangalore.

The law applicable to such dispute and then resolution shall be the law of India.

24. PROOF OF AUTHORISATION :

Authorized agents or should produce a certificate/letters from their manufacturers that they are the only authorized dealers for the supply of the goods.

25. LIQUIDATED DAMAGES :

In the case of supply of defective material or detection of defect, in the material after the supply, the supplier shall liable to pay liquidated damages in the sum equal to the cost of similar suppliers in good condition, along with a penalty of ten percent thereon.

ENTERING INTO CONTRACT :

Whenever the value of purchases exceed Rs.10,000 in each case, the procurement authority shall enter into a contract with the supplier incorporating all the particulars of the purchase order including penalty clauses on the stamp paper of the value of Rs.100=00, before issue of purchase order. The contract in form (Section-XI) shall be signed both by the supplier and the Procurement Authority.

Successful Tenderer shall execute agreement within specified period.

The Tenders for supply remain open for acceptance for a period of 60 days from the date of opening tenders. If any tenderer withdraws his tender before the said period the EMD shall be forfeited.

PLACE: Bangalore
DATE :

DIRECTOR
KIDWAI MEMORIAL INSTITUTE OF ONCOLOGY
&
TENDER INVITING AUTHORITY
BANGALORE.

SECTION III

PACKAGE _ - 1 FOR SUPPLY OF ANTI CANCER DRUGS

A. DOCUMENTS TO BE PLACED IN COVER-I

NOTES:

1. Tender document in original
2. Demand Draft towards Earnest Money Deposit.
3. Sales Tax Clearance Certificate for the accounting year 2012-2013 latest
4. List of items supplied to various International Agencies Major Government Hospitals with quantities Including supply to programmes sponsored by WHO/Unicef, if any.
5. Manufacturing License duly renewed up to date/ license validity certificate along with approved list/ permission letter.
6. Manufacturers Authorization Form.
7. Bureau of Indian Standard Certification. Where ever applicable.
8. Sample submission wherever necessary.
9. All the Certificates mentioned in prerequisites and Technical Specification for procurement of Drugs.
10. Quality Analysis report by Accredited Labs.

B. DOCUMENTS TO BE PLACED IN COVER-II

Only Financial Bid

PACKAGE - 2 FOR SUPPLY OF REAGENTS TO BLOOD BANK

A. DOCUMENTS TO BE PLACED IN COVER-I

NOTES:

1. Tender document in original
2. Demand Draft towards Earnest Money Deposit.
3. Sales Tax Clearance Certificate for the accounting year 2012-2013 latest
4. List of items supplied to various International Agencies Major Government Hospitals with quantities Including supply to programmes sponsored by WHO/Unicef, if any.
5. Manufacturing License duly renewed up to date/ license validity certificate along with approved list/ permission letter.
6. Manufacturers Authorization Form.
7. Bureau of Indian Standard Certification. Where ever applicable.
8. Sample submission wherever necessary.
9. All the Certificates mentioned in prerequisites and Technical Specification for procurement of Drugs.
10. Quality Analysis report by Accredited Labs.

B. DOCUMENTS TO BE PLACED IN COVER-II

Only Financial Bid

SECTION-IV

PACKAGE _ - 1 & 2 FOR SUPPLY OF ANTI CANCER DRUGS & REAGENTS TO BLOOD BANK

LIST ENCLOSED

SECTION V

PROFORMA FOR SUBMISSION OF SAMPLES

(Ref.Clause 11)

PACKAGE - 1 FOR SUPPLY OF ANTI CANCER DRUGS / REAGENTS TO BLOOD BANK

SL.NO	NAME OF THE ITEM	QUANTITY OF SAMPLE SUBMITTED

Total number of sample submitted: Signature Place

Total number of attachment used : with seal Date

Acknowledgement of the person

Receiving the sample/s with date

and seal

NOTE: If the space provided is inadequate, use additional sheet/s and ensure that the format is the same. If more than one sheet is used, each page shall be

serially numbered and signed in full and at the end the number of sheets used shall be indicated in figures and words. And total number of items quoted shall also be mentioned in words and figures.

SECTION -VI

TENDER OFFER FORM

To

The Director
Kidwai Memorial Institute of Oncology
Dr.M.H.Marigowda Road
Bangalore-560 029.

Sir,

Having examined the tender documents in connection with for supply of Anti Cancer Drugs / Reagents to Blood Bank to your Institute called by you, I/We, the undersigned offer to supply and deliver the Anti Cancer Drugs & Reagents in conformity with the terms & conditions of the tender at the rates quoted in the tender documents if awarded in my/our favour.

I/We undertake if our quotation is accepted I/We will deliver the goods in accordance with the delivery schedule.

I/We understand that you are not bound to accept the lowest or any quotations you may receive.

DATE:

Signature

PLACE: Bangalore.

Name in capital (Capacity)

Seal of the Firm

NOTE:

1. The quotation shall be indicated in the format attached
2. Quotations not in the format will be rejected.

SECTION-VII

Format of Enclosures

FOR SUPPLY OF Anti Cancer Drugs & Reagents to Blood Bank

Format for:-

1. Manufacturers Authorization form

FORMAT

MANUFACTUERS AUTHORIZATION FORM

NO. DATED:

To

M/s. _____

_____

_____

Dear Sir,

Sl.No. _____

We _____ who are established and reputable manufacturers of _____ having factories at _____ and _____ do hereby authorize M/s. _____ (Name & address of Agents) to quote, negotiate, and conclude the contract with you against Sl.No._____ for the above goods manufactured by us.

We hereby extend our full guarantee and warranty as per the General Conditions of tender for the goods offered for supply against this tender by the above firm against this Sl.No.

Yours faithfully,

(Name)

For and

On behalf of M/s._____

(Name of Manufacturers)

Note: This letter of authority should be on the letterhead of the manufacturing concern and should be signed by a person competent and having the power of Attorney to bind the manufacturer.

Place:

Date:

SECTION- VIII

CONTRACT FORM (STAMP PAPER OF Rs.100=00)

KIDWAI MEMORIAL INSTITUTE OF ONCOLOGY

This Agreement for supply of goods/providing services to the Department/Office of Kidwai Memorial Institute of Oncology is executed on the …….. (Day) of …… (Month) 20….. to 20…….. (year) by the provider M/s. …… represented by …… hereinafter called the VENDOR of the one part and the authorized officer of Kidwai Memorial Institute of Oncology to initiate action to procure goods/services) hereinafter called the PROCUREMENT AUTORITY (PA) of the other part.

Whereas, the VENDOR responded to the tender notification/enquiries of the PROCUREMENT AUTHORITY and offered to supply goods/provide services specified in the tender notification/enquiries at the rates and as per terms and conditions stipulated therein.

The PROCUREMENT AUTHORITY, having satisfied with the rates offered and other terms of the VENDOR and with the approval/sanction of the competent authority vide order No. / File No…… dated ……
Issued purchase orders vide his No. …….. Dated to the VENDOR for supplying goods/providing services fully described in the SCHEDULE at rates indicated there-against.

The VENDOR agrees to supply the good/provide services described in the Schedule according to the specification/requirement and within the time specified. Further, the VENDOR agrees for the payment terms specified in the schedule besides to furnish registration details pertaining to Sales Tax and IT PAN details etc., to the PROCUREMENT AUTHORITY.

The VENDOR also agrees to indemnify any loss arising on account of delay in supplying goods/providing services or due to any omissions and commissions in this behalf.

The PROCUREMENT AUTHORITY agrees to settle the bills of the VENDOR after receipt of the goods in good condition/installation and after satisfactory rendering of the required services by the VENDOR, as per the Purchase Order issued in this behalf (specify other conditions specifically agreed upon).

SCHEDULE:

SL.No	Particulars	Specification	No. of Units	Rate per unit	Time within which to be supplied

1) Place of delivery/office where service is to be provided…….
2) Date of commencement and completion ……..
3) Payment Terms …….
4) Special conditions if any, agreed upon:

VENDOR PROCUREMENT AUTHORITY

Witnesses

	Name	Address	Signature
1.			
2.			

GENERAL INSTRUCTIONS :

Please refer to the guidelines for further information on how to complete this form and on the implementation of the scheme.

Form should be completed using a typewriter to ensure legibility.
A cross should be placed in squares as appropriate to indicate which stands apply.

Additional sheets should be appended, as necessary to accommodate remarks and explanations.

EXPLANATORY NOTES :

This certificate, which is in the format recommended by WHO, established the status of the pharmaceutical product and of the applicant for the certificate in the exporting country. It is for a single product only since manufacturing arrangements and approved information for different dosage forms and different strengths can vary.

Use whenever possible, international Non-proprietary names (INNs) or National Non-proprietary Names.

A qualitative listing of other ingredients contained in the dosage form should be appended.

When applicable, append details of any restriction applied to the sale, distribution, or administration of the product that is entered on the product license.

Specify whether the person responsible for placing a product on the Market :

Manufacturers the active ingredients and the finished dosage form :

Manufacturers the finished dosage form :

Packages and/or labels is a finished dosage form manufactured by an independent company or

Is involved in none of the above.

Indicate, when applicable, if the license is provisional, pending technical review.

This refers to the document, prepared by certain national regulatory authorities, that summarizes the technical basis on which the product has been licensed.

In this circumstance, permission for issuance of the certificate is required from the product license holder.

Please indicate the reason the applicant has provided for not requesting registration :

The product has been developed exclusively for the treatment of conditions – particularly tropical diseases – not endemic in the country of export.

The product has been reformulated with a view to improving its stability under tropical conditions.

The product has been reformulated to exclude exceipients not approved for use in pharmaceuticals products in the country of import.

The product has been reformulated to meet a different maximum dosage limit for an active ingredient.

Any other reason, please specify.

The requirements for good practices in the manufacturer and quality control of drugs referred to in the certificate are those adopted by the Twenty eighth World Health Assembly in its resolution WHA 28.65 (see WHO Official Records, No.226,1975,part I, Annex 12). Proposals for the amendment of these requirements are included in the Thirty second report of the WHO Expert Committee on Biological standardization (WHO technical report Series, No.822, 1992, Annex I).

11. This section is to be completed when the product – license holder or applicant conforms to status (c or d) as described in note 5 above. It is of particular importance when foreign contractors are involved in the product. In these circumstances the applicant should supply the certifying authority with information to identify the contracting parties responsible for each stage of manufacture of the finished dosage form, and to indicate the extent and nature of any controls exercised over each of these parties.

KIDWAI MEMORIAL INSTITUTE OF ONCOLOGY

DR. M.H. MARIGOWDA ROAD, BANGALORE – 560 029.

Prerequisites and Technical Specifications for Procurement of Drugs

1. All the drugs must be of Generic (International non Proprietary name)formulation, if generic formulation of the drug is not available then the brand name may be considered.
2. The Tenderer (Manufacturer & Supplier) shall submit authorization letter from the manufacturer.
3. The Tenderer has to submit samples of the Items Quoted Items are Selected only on the basis of quality tested by samples given, and by experts (Along with quality analysis by a accredited labs)
4. The bidder should furnish information on past supplies and satisfactory performance.
5. The Tenderer should have experience of supplying materials to major Government and corporate hospitals.
6. The bidder should furnish documentary evidence that is end user certificate in support of satisfactory of the products and service rendered.
7. The drug manufacturer/supplier must have valid Drug License, (Form-25A, Form-28A, Form-28D etc.) VAT License, ISO Certificate and Authentic License for conducting Sterilization by Gamma Radiation, and also their performance Certificate.
8. The Drug manufacturer must have Sales Tax Clearance.
9. The Manufacturer of the drugs and consumables including Anticancer Drugs shall furnish a Certificate from the competent authority such as Central Drugs Standard Control Organization (CDSCO) that the manufacturer of the Pharmaceuticals is licensed to manufacture these products. (Form-25A, Form-28A, Form-28D etc.)
10. The manufacturer should not have any conviction against them by Central Drug Standard Control Organization (CDSCO) or any other such organization who issue license to manufacture the drugs including Anticancer Drugs.
11. The manufacturer should comply with WHO prescribed good manufacturing practice.
12. The Bidder shall quote only for drugs for which analytical reports are available. The vendor has to provide copies of product test along with each supply.
13. The manufacture should have minimal annual turnover of rupees 25 crores. (Attested by a Chartered Accountant for previous years)

14. The required packing standards and label for drugs and consumables including Anticancer Drugs must meet the latest requirements of the World Health Organization (WHO) Good manufacturing practices (GMP) standards in all respects.
15. All the Tablets/Capsules must be supplied in blisters or Aluminium packing only. No loose drugs will be procured.
16. The committee is not bound to accept the lowest tender rate considering the Technical Aspects.
17. The supplier will also be required to provide the Purchaser with access to its manufacturing facilities to aspect the compliance with the GMP requirements and quality control mechanisms.
18. The supplier should furnish Manufacturing and Marketing Certificate issued by Central / State Drug Controller.
19. The Supplier should furnish copy of last 3 years Sales Tax Returns (in case new manufacturer one year)
20. The eliminate sole dependence on one supplier, the next two lower suppliers willing to match the lowest price will also be approved.
21. If any information or document furnished by the Tender is found to be incorrect or misleading at any stage their tender will be rejected.
22. If any mortality is reported which is attributed to the drug administration and confirmed by the concerned doctors, the supplier should take back the drugs at their risk and cost.
23. If any mortality as described in 23 occurs and if the patient's relatives claim for any compensation the manufacturer/supplier are liable to pay the same.
24. If any other legal issues arrive because of the Administration of these Anti Cancer Drugs and also due to the side effects caused by Administration of these drugs the manufacturer / Supplier are liable to pay the cost and compensation as decided by the Court or by any other Legal Authority (Under the Jurisdiction of Bangalore City only)
25. The bidder should have manufactured and marketed the specific Pharmaceuticals to be procured for at least a period of three years. (If he is new Manufacturer, in case rate drug one year)

Sl. No.	Code No.	Description	
1	DI /AC - 01	Cap. Estramustine Phophate Sodium140 mg	
2	DI /AC - 02	Cap. Etoposide 100 mg	
3	DI /AC - 03	Cap. Etoposide 50 mg	
4	DI /AC - 04	Cap. Hydroxyurea 100 mg, for 10	
5	DI /AC - 05	Cap. Hydroxyurea 500 mg, for 10	
6	DI /AC - 06	Cap. Imitinib Mesylate 100 mg, for 10	
7	DI /AC - 07	Cap. Imitinib Mesylate 400 mg, for 10	
8	DI /AC - 08	Cap. Lenalidomide 10 mg	
9	DI /AC - 09	Cap. Lenalidomide 15 mg	
10	DI /AC - 10	Cap. Lenalidomide 25 mg	
11	DI /AC - 11	Cap. Lenalidomide 5 mg	
12	DI /AC - 12	Cap. Lomustine 40 mg	
13	DI /AC - 13	Cap. Nilotinib Hydrochloride 150 mg	
14	DI /AC - 14	Cap. Nilotinib Hydrochloride 200 mg	
15	DI /AC - 15	Cap. Tegafur 100 mg	
16	DI /AC - 16	Cap. Tegafur 200 mg	
17	DI /AC - 17	Temozolamide 100 mg, 5Caps	
18	DI /AC - 18	Cap. Temozolamide 250 mg, 5 Caps	
19	DI /AC - 19	Cap. Temozolamide 20 mg, 5 Caps	
20	DI /AC - 20	Cap. Thalidomide 100 mg, for 10	
21	DI /AC - 21	Cap. Thalidomide 50 mg, for 10	
22	DI /AC - 22	Inj. 5-Fluorouracil 1000 mg	
23	DI /AC - 23	Inj. 5-Fluorouracil 250 mg	
24	DI /AC - 24	Inj. 5-Fluorouracil 500 mg	
25	DI /AC - 25	Inj. Amifostine 500 mg	
26	DI /AC - 26	Inj. Arsenic Trioxide 10 mg	
27	DI /AC - 27	Inj. Bendamustine Hydrochloride100 mg	
28	DI /AC - 28	Inj. Bevacizumab 100mg	
29	DI /AC - 29	Inj. Bleomycin 15 mg	
30	DI /AC - 30	Inj. Bortezomib 2 mg	
31	DI /AC - 31	Inj. Bortezomib 3.5 mg	
32	DI /AC - 32	Inj. Cabazitaxel 60 mg	
33	DI /AC - 33	Inj. Calcium Leucovorin 15 mg	
34	DI /AC - 34	Inj. Calcium Leucovorin 3 mg	
35	DI /AC - 35	Inj. Calcium Leucovorin 50 mg	
36	DI /AC - 36	Inj. Carboplatin 150 mg	
37	DI /AC - 37	Inj. Carboplatin 450 mg	
38	DI /AC - 38	Inj. Carboplatin 600 mg	
39	DI /AC - 39	Inj. Caspofungin Acetate 50 mg	
40	DI /AC - 40	Inj. Caspofungin Acetate 70 mg	
41	DI /AC - 41	Inj. Cetuximab 100 mg	
42	DI /AC - 42	Inj. Cetuximab 500 mg	
43	DI /AC - 43	Inj. Chlorambucil 5 mg	
44	DI /AC - 44	Inj. Cisplatin 10 mg	
45	DI /AC - 45	Inj. Cisplatin 100 mg	
46	DI /AC - 46	Inj. Cisplatin 50 mg	
47	DI /AC - 47	Inj. Cladribine 1 mg /ml	
48	DI /AC - 48	Inj. Cyclophosphamide 1000 mg	

49	DI /AC - 49	Inj. Cyclophosphamide 200 mg	
50	DI /AC - 50	Inj. Cyclophosphamide 500 mg	
51	DI /AC - 51	Inj. Cytarabine 1000 mg	
52	DI /AC - 52	Inj. Cytarabine 500 mg	
53	DI /AC - 53	Inj. Cytarabine100 mg	
54	DI /AC - 54	Inj. Dacarabzine 100 mg	
55	DI /AC - 55	Inj. Dacarabzine 200 mg	
56	DI /AC - 56	Inj. Dacarabzine 500 mg	
57	DI /AC - 57	Inj. Dactinomycin 500 mcg	
58	DI /AC - 58	Inj. Dannorubicin 20 mg	
59	DI /AC - 59	Inj. Darbepoetin Alfa 100 mcg	
60	DI /AC - 60	Inj. Darbepoetin Alfa 200 mcg	
61	DI /AC - 61	Inj. Decitabine 50 mg	
62	DI /AC - 62	Inj. Decitabine Lyphilzed 50 mg	
63	DI /AC - 63	Inj. Docetaxel 120 mg	
64	DI /AC - 64	Inj. Docetaxel 20 mg	
65	DI /AC - 65	Inj. Docetaxel 80 mg	
66	DI /AC - 66	Inj. Doxorubicin 10 mg	
67	DI /AC - 67	Inj. Doxorubicin 50 mg	
68	DI /AC - 68	Inj. Epirubicin 10 mg	
69	DI /AC - 69	Inj. Epirubicin 100 mg	
70	DI /AC - 70	Inj. Epirubicin 50 mg	
71	DI /AC - 71	Inj. Erythropoietin 10 ku	
72	DI /AC - 72	Inj. Erythropoietin 40 ku	
73	DI /AC - 73	Inj. Etoposide 100 mg	
74	DI /AC - 74	Inj. Ferric Carboxymaltose 100 mg	
75	DI /AC - 75	Inj. Ferric Carboxymaltose 500 mg	
76	DI /AC - 76	Inj. Filgrastim 300 mg PFS	
77	DI /AC - 77	Inj. Filgrastim 300 mg Vial	
78	DI /AC - 78	Inj. Fludarabine Phospate 50 mg	
79	DI /AC - 79	Inj. Fulvestrant 250 mg	
80	DI /AC - 80	Inj. Fulvestrant 500 mg	
81	DI /AC - 81	Inj. Gemcitabine HCl 1.4 g	
82	DI /AC - 82	Inj. Gemcitabine HCl 1g	
83	DI /AC - 83	Inj. Gemcitabine HCl 200 mg	
84	DI /AC - 84	Inj. Goserelin Acetate 10 .8 mg	
85	DI /AC - 85	Inj. Ibondronate Sodium 6 mg	
86	DI /AC - 86	Inj. Idarubicin Hydrochloride 5 mg	
87	DI /AC - 87	Inj. Ifosfamide 0.5 g, with Mesna	
88	DI /AC - 88	Inj. Ifosfamide 1 g, with Mesna	
89	DI /AC - 89	Inj. Ifosfamide 2 g, with mesna	
90	DI /AC - 90	Inj. Interferon A 18 Miu	
91	DI /AC - 91	Inj. Interferon A 30 Miu	
92	DI /AC - 92	Inj. Interferon A 5 Miu	
93	DI /AC - 93	Inj. Interferon Alfa 3mil iu	
94	DI /AC - 94	Inj. Interferon Alfa 5 mil iu	
95	DI /AC - 95	Inj. Irinotecan Hydrochloride 100 mgs	
96	DI /AC - 96	Inj. Irinotecan Hydrochloride 40 mgs	
97	DI /AC - 97	Inj. Ixabepilone 15 mg	
98	DI /AC - 98	Inj. Ixabepilone 45 mg	
99	DI /AC - 99	Inj. L- Asparaginase 10000 iu	
100	DI /AC - 100	Inj. L- Asparaginase 5000 iu	
101	DI /AC - 101	Inj. Lenograstim 34	

102	DI /AC - 102	Inj. Leuprolide Acetate 11.5 mg	
103	DI /AC - 103	Inj. Leuprolide Acetate 22.5 mg	
104	DI /AC - 104	Inj. Leuprolide Acetate 3.5 mg	
105	DI /AC - 105	Inj. Liposomal Amphotericin B	
106	DI /AC - 106	Inj. Melphalan 2 mg	
107	DI /AC - 107	Inj. Melphalan 5 mg	
108	DI /AC - 108	Inj. Mercaptopurin 50 mg	
109	DI /AC - 109	Inj. Mesna 200 mg	
110	DI /AC - 110	Inj. Methotrexate 1000 mg	
111	DI /AC - 111	Inj. Methotrexate 50 mg	
112	DI /AC - 112	Inj. Methotrexate 500 mg	
113	DI /AC - 113	Inj. Methotrexate 15 mg	
114	DI /AC - 114	Inj. Methotrexate 25 mg	
115	DI /AC - 115	Inj. Mitomycin 10 mg	
116	DI /AC - 116	Inj. Mitomycin 2 mg	
117	DI /AC - 117	Inj. Mitomycin 40 mg	
118	DI /AC - 118	Inj. Mitoxantropone Hydrochloride 20 mg	
119	DI /AC - 119	Inj. Nimotuzumab 10 ml	
120	DI /AC - 120	Inj. Octreotide Acetate 10 mg	
121	DI /AC - 121	Inj. Octreotide Acetate 20 mg	
122	DI /AC - 122	Inj. Oxaliplatin 100 mg	
123	DI /AC - 123	Inj. Oxaliplatin 50 mg	
124	DI /AC - 124	Inj. Paclitaxel (Protien Bound) 100 mg	
125	DI /AC - 125	Inj. Paclitaxel 100 mg	
126	DI /AC - 126	Inj. Paclitaxel 260 mg	
127	DI /AC - 127	Inj. Paclitaxel 30 mg	
128	DI /AC - 128	Inj. Paclitaxel 300 mg	
129	DI /AC - 129	Inj. Peg-Filgrastim 6 mg	
130	DI /AC - 130	Inj. Peglated L Doxorubicin 10 mg	
131	DI /AC - 131	Inj. Peglated L Doxorubicin 20 mg	
132	DI /AC - 132	Inj. Peglated L Doxorubicin 50 mg	
133	DI /AC - 133	Inj. Pemetrexed Disodium 100mg	
134	DI /AC - 134	Inj. Pemetrexed Disodium 500mg	
135	DI /AC - 135	Inj. Pemsirolilumes 25 mg	
136	DI /AC - 136	Inj. Rasburicase 1.5 mg	
137	DI /AC - 137	Inj. Topotecan Hydrochloride 0.25 mg	
138	DI /AC - 138	Inj. Topotecan Hydrochloride 1 mg	
139	DI /AC - 139	Inj. Trabectedin 1 mg	
140	DI /AC - 140	Inj. Trastuzumab 440 mg	
141	DI /AC - 141	Inj. Vinblastine Sulfate 10 mg	
142	DI /AC - 142	Inj. Vincristine Sulfate1 mg	
143	DI /AC - 143	Inj. Vinorelbine Tartrate 10 mg	
144	DI /AC - 144	Inj. Vinorelbine Tartrate 50 mg	
145	DI /AC - 145	Inj. Zolendronic Acid 4 mg	
146	DI /AC - 146	Inj.Carmustine 100 mg	
147	DI /AC - 147	Inj.Nano-Patricle Paclitaxel 100 mg	
148	DI /AC - 148	Inj.Nano-Patricle Paclitaxel 30 mg	
149	DI /AC - 149	Inj.Nano-Patricle Paclitaxel 300 mg	
150	DI /AC - 150	Tab. Abiraterone Acetate 250 mg	
151	DI /AC - 151	Tab. Anastazole 1 mg , 1 tab	
152	DI /AC - 152	Tab. Aprepitant 125 mg	
153	DI /AC - 153	Tab. Aprepitant 80 mg	
154	DI /AC - 154	Tab. Bicalutamide 50 mg, for 1	

155	DI /AC - 155	Tab. Busulphan 2 mg	
156	DI /AC - 156	Tab. Capcetabine 150 mg for 1	
157	DI /AC - 157	Tab. Capcetabine 500 mg for 1	
158	DI /AC - 158	Tab. Chlorambucil 2 mg	
159	DI /AC - 159	Tab. Chlorambucil 5 mg	
160	DI /AC - 160	Tab. Cyclophosphamide 50 mg	
161	DI /AC - 161	Tab. Dasatinib 20 mg	
162	DI /AC - 162	Tab. Dasatinib 50 mg	
163	DI /AC - 163	Tab. Dasatinib 70 mg	
164	DI /AC - 164	Tab. Deferasirox 250 mg	
165	DI /AC - 165	Tab. Deferasirox 500 mg	
166	DI /AC - 166	Tab. Doxifluridine 200 mg	
167	DI /AC - 167	Tab. Eltrombopag Olamine 25 mg	
168	DI /AC - 168	Tab. Erlotinib Hydrochloride 100 mg	
169	DI /AC - 169	Tab. Erlotinib Hydrochloride 150 mg	
170	DI /AC - 170	Tab. Everolimus 10 mg	
171	DI /AC - 171	Tab. Everolimus 5 mg	
172	DI /AC - 172	Tab. Exemestine 25 mg	
173	DI /AC - 173	Tab. Fludarabine Phospate 50 mg	
174	DI /AC - 174	Tab. Flutamide 250 mg	
175	DI /AC - 175	Tab. Gefitinib 250 mg	
176	DI /AC - 176	Tab. Lapatinib Ditosylate 250 mg	
177	DI /AC - 177	Tab. Letrozole 2.5 mg	
178	DI /AC - 178	Tab. Megestrol Acetate 40 mg	
179	DI /AC - 179	Tab. Melphalan 2 mg, 25 tabs	
180	DI /AC - 180	Tab. Melphalan 5 mg, 25 tabs	
181	DI /AC - 181	Tab. Mercaptopurine 50 mg	
182	DI /AC - 182	Tab. Mesna 200 mg	
183	DI /AC - 183	Tab. Methotrexate 10 mg, for 10	
184	DI /AC - 184	Tab. Methotrexate 2.5 mg, for 10	
185	DI /AC - 185	Tab. Pazopanib Hydrochloride 200 mg	
186	DI /AC - 186	Tab. Pazopanib Hydrochloride 400 mg	
187	DI /AC - 187	Tab. Procarbazine 50 mg, for 10	
188	DI /AC - 188	Tab. Sorafenib Tosylate 200 mg	
189	DI /AC - 189	Tab. Sunitinib Malate 12.5 mg	
190	DI /AC - 190	Tab. Sunitinib Malate 25 mg	
191	DI /AC - 191	Tab. Sunitinib Malate 50 mg	
192	DI /AC - 192	Tab. Tamoxifen 10 mg, for 10	
193	DI /AC - 193	Tab. Tamoxifen 20 mg, for 10	
194	DI /AC - 194	Tab. Thiogaunine 40 mg	
195	DI /AC - 195	Tab. Tibolone 2.5 mg	
196	DI /AC - 196	Tab. Tretinoin 10 mg	

KIDWAI MEMORIAL INSTITUTE OF ONCOLOGY

DR. M.H. MARIGOWDA ROAD, BANGALORE – 560 029.

List of Reagents for Blood Bank

01. Anti –A1 Lectin – (5ml Vials)
02. Coomb Reagent – (AHG) Anti Ig G + Anti C3d – (10 ml. Vials)
(AHG) Anti Ig G only – (10 ml. Vials)
03. Malaria Rapid Card Test
04. HCV Elisa Test Kit
05. Hemoglobin Estimation Cuvettes (for point of care testing)
06. Pooled Reagent Red Cells for Red Cell Antibody screeing and identification
07. Column agglutination (glass bead) Technology Cassettes for crossmatch in coombs phase

Technical Specifications for Diagnostic Kits

HCV ELISA:

1. 3^{RD} Generation Assay
2. Combination of HCV Antigens for E1, E2, Core, NS3, NS4 & NS5
3. Breakaway microwell strips
4. Should be based on indirect Elisa Principle
5. Colour coded reagents to monitor procedural steps
6. Short assay procedure (<120 minutes)
7. Longer shelf life : 15 months at $2\text{-}8^{0}$ c

MALARIA RAPID CARD TEST

Rapid qualitative, one-step immunoassay based on the immunochromatographic principle for the detection of Malaria P f/p.v antibodies in human serum or plasma